Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma - Cloughesy, TF; Mochizuki, AY; Orpilla, JR; Hugo, W; Lee, AH; Davidson, TB (Nat Med, 2019)